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Abstract: Hypospadias is a common form of congenital atypical sex development that is often associated with other congenital comorbidities. Many genes have been associated with the condition, most
commonly single sequence variations. Further investigations of recurrent and overlapping copy number variations (CNVs) have resulted in the identification of genes and chromosome regions associated
with various conditions, including differences of sex development (DSD). In this retrospective study,
we investigated the DECIPHER database, as well as an internal institutional database, to identify
small recurrent CNVs among individuals with isolated and syndromic hypospadias. We further
investigated these overlapping recurrent CNVs to identify 75 smallest regions of overlap (SROs) on
18 chromosomes. Some of the genes within these SROs may be considered potential candidate genes
for the etiology of hypospadias and, occasionally, additional comorbid phenotypes. This study also
investigates for the first time additional common phenotypes among individuals with hypospadias
and overlapping CNVs. This study provides data that may aid genetic counseling and management
of individuals with hypospadias, as well as improve understanding of its underlying genetic etiology
and human genital development overall.
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1. Introduction
Hypospadias is a form of congenital atypical sex development that involves a urethral
meatus located on the ventral aspect of the penis, scrotum, or perineum. It is very common,
with an estimated incidence of one per 125 to one per 300 live male-assigned births, which
has increased in frequency over the past few decades [1]. While most cases are distal to
the neck of the glans, known as anterior hypospadias, the remaining cases have more
proximal meatuses, known as middle (penile) or posterior (penoscrotal, scrotal, or perineal)
hypospadias. Hypospadias is in contrast to epispadias, in which the urethral meatus is
found on the dorsal penis.
Hypospadias can lead to both cosmetic and functional impairment, but only when
severe. Infants with hypospadias, especially posterior cases, more frequently exhibit other
congenital comorbidities compared to infants born without hypospadias [2]. In addition,
people born with hypospadias are often found to have other urogenital abnormalities,
especially cryptorchidism (undescended testis or testes) [2,3].
Despite decades of research, the etiology of most cases is unknown, likely a mix
of environmental and hormonal factors with monogenic and/or multifactorial genetic
features [2,4]. Specifically, it is likely due to a mix of hypoandrogenic states combined with
pre-existing genetic susceptibility [5]. Environmental factors repeatedly associated with
hypospadias include maternal hypertension and pre-eclampsia, placental insufficiency,
maternal intrauterine exposure to diethylstilbestrol, being small for gestational age, and
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low birth weight [2,4]. About 7–25% of cases occur as part of familial clustering [6–8], and
in pedigree and twin studies, heritability has been reported as anywhere from 55 to 77% [9],
suggesting that genetic factors indeed play a strong role in causing the phenotype.
Over five decades of research have revealed many genes that are associated with
hypospadias, most commonly involving sequence variations [2,10–18] (Table 1). Although
several variants have been described as potentially causing hypospadias, researchers
largely agree that very few cases of isolated hypospadias—especially milder ones—are
caused by single sequence variations [2]. A limited but growing body of research suggests that epigenetic changes may contribute to differences of male sexual development,
including hypospadias [19].
Table 1. Selected previously defined genes and regions in hypospadias.
Chromosome
Locus
(GRCh37/hg19)

Common
Variation

SRO from Our
Study (Gene)

Size (kb)

Reference

LHCGR
SRD5A2
ZEB2
HOXA13
SHH
CYP17A1
WT1
CYP11A1
ADAT3
RBFOX2
DGKK
MID1
AR
MAMLD1
Regions
7q32.2-q36.1
13q33-q34

2p16.3
2p23.1
2q22.3
7p15.2
7q36.3
10q24.32
11p13
15q24.1
19p13.3
22q12.3
Xp11.22
Xp22.2
Xq12
Xq28

Sequence
Sequence
Sequence
Sequence
Sequence
Sequence
Sequence
Sequence
Sequence
Sequence
Sequence
Sequence
Sequence
Sequence

None
None
None
None
SRO024
None
SRO036
None
None
SRO063
None
None
None
None

N/A
N/A
N/A
N/A
473.21
N/A
375.54
N/A
N/A
83.35
N/A
N/A
N/A
N/A

Vezzoli et al. 2015 [9]
OMIM #607306 [10], HPA [11]
van der Zanden et al. 2012 [2]
OMIM #142959 [10]
Carmichael et al. 2013 [12]
Singh et al. 2018 [13]
van der Zanden et al. 2012 [2]
Lara-Velazquez et al. 2017 [14]
Thomas et al. 2019 [15]
White et al. 2020 [16]
HPA [11]
HPA [11]
OMIM #300633 [10]
OMIM #300120 [10]; HPA [11]

-

CNV
CNV

N/A
N/A

OMIM #146450 [10]
Andresen et al. 2010 [17]

Xp11.22

-

CNV

None
None
SRO0070-74
(HUWE1)

1.58

OMIM #300856 [10]

Genes

The advent of chromosomal microarray analysis (CMA) allows for the identification of
copy number variations (CNVs) across the entire genome. Further investigations of recurrent and overlapping deleted and/or duplicated regions have resulted in the identification
of genes and regions associated with various conditions, including differences of sex development (DSD) [20]. These documented CNVs are typically larger in size (≥1.5 Mb) [21]. In
this retrospective study, we investigated the DECIPHER database (DatabasE of genomiC
varIation and Phenotype in Humans using Ensembl Resources) of deletions and duplications detected in patients with various clinical phenotypes [22], as well as an internal
institutional database, to identify small recurrent CNVs among individuals with isolated or
syndromic hypospadias. We further investigated these overlapping recurrent CNVs present
in at least three patients to identify the smallest regions of overlap (SROs) between their
CNVs, and the genes within these intervals, some of which can be considered potential candidate genes for the etiology of hypospadias. We then constructed a whole-genome CNV
map from these SROs to illustrate the global genomic view of hypospadias. Furthermore,
this study investigates for the first time additional common phenotypes among individuals
with hypospadias and overlapping CNVs. This study expands genotype–phenotype correlation and provides data that may aid genetic counseling and management of individuals
with hypospadias.
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2. Results
The DECIPHER query returned 469 hypospadias cases, for which the number of
reported copy number variants ranged from 0 to 7. About 76% (357/469) only had one
reported variant, while the rest had at least two variants [22]. The majority were 46XY;
however, we also found ten cases reported as 46XX, 22 reported as “other” or “unknown”,
and one reported with sex chromosome aneuploidy [22].
Our CMA approach identified 75 small SROs (Figure 1) with a mean size of 136.04 kilobase
pairs (kb) (range, 0.21–574.57 kb), and a mean of 8.9 individuals with overlapping CNVs (range,
3–28) (Figure 2; Table 2 and S1). Thirty-one of the 75 SROs (41%) included at least one CNV of
a patient from our center. While most SROs included a mixture of deletions and duplications,
7 SROs exclusively included deletions, while 8 included only duplications. SROs were found
across the genome, with the highest frequencies of SROs found on chromosomes 22 (17 SROs)
and 1 (9 SROs); no SROs were identified on chromosomes 3, 14, 19, 20, 21, or the Y chromosome
(Figure 3).
Of the loci given for the nine hypospadias phenotype entries in OMIM® , we found
four SROs within the locus for susceptibility to X-linked hypospadias (HYSP4, Xp11.22) [11].
There was only one known gene within these SROs (HUWE1), which was identified as
a candidate gene. We also identified SROs overlapping with the following genes with
established associations with hypospadias: RBFOX2, SHH, and WT1.
Several studies have used other methods to identify CNVs potentially involved in
hypospadias, although they typically use smaller sample sizes and do not discriminate based
on CNV size. Such studies have associated duplications of 17q12 [23], as well as duplications
of Ypter-Yq11.223 and loss of the remainder of chromosome Y (mosaic dicentric Y) [21], but
neither overlapped with our SROs. Similarly, we did not find any SROs overlapping potential
hypospadias susceptibility loci identified on chromosomes 2, 7 9, and 10 in two studies using
familial linkage analysis [24,25]. However, our findings support one study which described
clinically significant CNVs on chromosomes 2, 5, 12, 16, and X [26]: we identified 3 SROs
within their CNV at 16p11.

Figure 1. Distribution of SRO size.
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Figure 2. SRO Distribution across the Genome. Chromosomal locations for each SRO were used
to construct a BED (Browser Extensible Data) file which was imported into Chromosome Analysis
Suite (ChAS; Affymetrix, Inc./Thermo Fisher Scientific, Santa Clara, CA, USA) as a track. Green stars
indicate SROs or clusters of SROs composed strictly of duplications, red stars indicate deletions, and
blue stars indicate SROs that featured both types of CNVs.

Figure 3. SRO frequency across chromosomes.
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Table 2. Candidate genes in hypospadias.
SRO from
Our Study

Chromosome
Locus
(GRCh37/hg19)

CNV Type

Size (kb)

SRO001

1p36.33

Del/Dup

68.05

SRO002

1q21.1

Del/Dup

81.26

SRO003

1q21.1

Del/Dup

29.44

SRO004

1q21.1

Del/Dup

103.47

SRO005

1q21.1-21.2

Del/Dup

341.53

SRO006
SRO007
SRO008

1q31.1
1q44
1q44

Del
Del/Dup
Del/Dup

251.69
8.65
15.32

SRO009

1q44

Del/Dup

178.41

SRO010
SRO011
SRO012
SRO013
SRO014
SRO015
SRO016
SRO017

2q37.3
4q35.2
4q35.2
4q35.2
4q35.2
4q35.2
4p16.1
4p16.1

Del/Dup
Del/Dup
Del/Dup
Del/Dup
Del/Dup
Del/Dup
Del/Dup
Del/Dup

3.55
481.63
9.73
94.01
3.61
38.47
148.71
68.85

SRO018

5q35.3

Dup

237.41

SRO019

6q27

Del/Dup

3.77

SRO020

6q27

Del/Dup

235.235

SRO021
SRO022
SRO023
SRO024
SRO025
SRO026

7q22.1
7q36.2
7q36.2
7q36.3
7p15.2
8p22

Del/Dup
Del/Dup
Del/Dup
Del/Dup
Del
Del/Dup

133.74
12.67
22.22
473.21
112.98
88.73

SRO027

9q34.3

Del

204.21

SRO028

9p22.2-22.1

Del

337.25

SRO029
SRO030
SRO031
SRO032
SRO033
SRO034
SRO035

9p24.1
9p24.1
10p14
11q23.3
11q25
11q25
11p14.1

Del
Del/Dup
Del/Dup
Del/Dup
Del/Dup
Del/Dup
Del

159.76
333.12
155.6
54.78
378.38
186.74
4.62

SRO036

11p13

Del/Dup

375.54

SRO037

11p13

Del/Dup

112.5

Genes
ATAD3A, ATAD3B,
ATAD3C
ANKRD35, GNRHR2,
ITGA10, LIX1L, PEX11B,
RBM8A *
ANKRD35, NUDT17,
PIAS3 *
POLR3C, RNF115
BCL9, CHD1L, LINC00624,
OR13Z1P, OR13Z2P,
OR13Z3P
LINC01036
AKT3 *
SMYD3
OR2L13, OR2M1P,
OR2M2, OR2M3, OR2M4,
OR2M5
MTERFD2, SNED1 *
ADAM20P3, ZFP42
RNU6-173P, TRIML2
MIR4798
SORCS2
DBN1 *, F12, GRK6,
LMAN2, MXD3, NSD1 *,
PFN3, PRELID1, PRR7,
PRR7-AS1, RAB24, RGS14,
RN7SL562P, SLC34A1
C6orf123 (lncRNA)
FAM120B, PDCD2,
PSMB1, TBP *
CUX1 *
DPP6
SHH
SNX10
MSR1
NACC2, C9orf69, LHX3,
QSOX2
ADAMTSL1 *, MIR3152,
RN7SKP258
ERMP1, KIAA1432
PTPRD *
LINC00707
GRIK4
B3GAT1, GLB1L2
BDNF *
CCDC73, EIF3M *,
HNRNPA3P9, WT1,
WT1-AS
EHF *

Most Common
Comorbid Phenotype **

Ventricular septal defect

Hypotonia
Feeding difficulties in infancy
Feeding difficulties in infancy

Hypertelorism

Hypoplastic nail

Congenital heart defect

Cryptorchidism
Anteverted nares
Anteverted nares
Abnormality of the pinna

Micrognathia
Short stature
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Table 2. Cont.
SRO from
Our Study

Chromosome
Locus
(GRCh37/hg19)

CNV Type

Size (kb)

SRO038

11p15.5

Del/Dup

323.55

SRO039

12q24.33

Del/Dup

574.57

SRO040

13q34

Del

17.78

SRO041

15q11.2

Del/Dup

490.07

SRO042

16p13.11

Dup

88.17

SRO043

16p11.2

Dup

214.84

SRO044

16p11.2

Del/Dup

21.6

SRO045

16p11.2

Del/Dup

516.64

SRO046
SRO047
SRO048

16p13.3
16q24.2
16p13.2

Del/Dup
Dup
Del/Dup

121.78
99.1
37.53

SRO049

17p13.3

Del/Dup

251.23

SRO050

17q23.2

Del/Dup

314.38

SRO051

17p13.1

Del/Dup

4.52

SRO052

18p11.31

Del/Dup

429.94

SRO053
SRO054
SRO055
SRO056
SRO057
SRO058

22q11.1
22q11.21
22q11.21
22q11.21
22q11.21
22q11.22

Del/Dup
Del/Dup
Del/Dup
Del/Dup
Del/Dup
Del/Dup

2.19
77.94
8.18
29.74
13.9
34.4

SRO059

22q11.22

Del/Dup

85.87

SRO060
SRO061

22q11.22
22q11.22

Del/Dup
Del/Dup

28.54
9.29

Genes
ATHL1, B4GALNT4,
BET1L, CICP23, IFITM1,
IFITM2, IFITM3, IFITM5,
LINC01001, NLRP6, ODF3,
OR4F2P, PSMD13 *,
RIC8A, RNU6-447P,
SCGB1C1, SIRT3
DDX51, EP400 *,
EP400NL, FBRSL1,
GALNT9, MUC8, NOC4L,
SNORA49
COL4A1 *
CYFIP1 *, ELMO2P1,
GOLGA8I, NIPA1, NIPA2
*, TUBGCP5, WHAMMP3
ABCC1, ABCC6
ATP2A1, ATXN2L *, CD19,
LAT, MIR4517, MIR4721,
NFATC2IP, RABEP2,
SH2B1 *, SPNS1, TUFM
SPN
ALDOA, ASPHD1,
C16orf54, C16orf92, CDIPT
*, CDIPT-AS1, DOC2A,
FAM57B, GDPD3, HIRIP3,
INO80E, KCTD13, KIF22,
MAPK3 *, MAZ *, MVP,
PAGR1, PPP4C, PRRT2,
QPRT, RN7SKP127,
SEZ6L2, SPN, TAOK2 *,
TBX6, TMEM219, YPEL3,
ZG16
RBFOX1 *, RNU6-457P
ZC3H18 *, ZFPM1
GRIN2A *
CRK *, INPP5K, MYO1C,
PITPNA *, PITPNA-AS1,
TUSC5, YWHAE *
BRIP1, INTS2 *, MED13 *,
RN7SL800P, POLRMTP1
DLGAP1 *, DLGAP1-AS1,
DLGAP1-AS2, IGLJCOR18,
RN7SL39P, RPL21P127,
RPL31P59, TGIF1
CLTCL1, KRT18P62
PI4KA
CRKL *, RN7SL389P
PPIL2, YPEL1
PPM1F, TOP3B
IGLV2-11, IGLV2-5,
IGLV2-8, IGLV3-10,
IGLV3-4, IGLV3-6,
IGLV3-7, IGLV3-9, MIR650
-

Most Common
Comorbid Phenotype **

Micrognathia

Long philtrum

Micropenis

Short neck

Low-set ears

Microcephaly
Preauricular skin tag
Hearing impairment
Cleft palate
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Table 2. Cont.
SRO from
Our Study

Chromosome
Locus
(GRCh37/hg19)

CNV Type

Size (kb)

Genes

SRO062
SRO063

22q11.23
22q12.3

Del/Dup
Del/Dup

1.74
83.35

SRO064

22q13.2

Dup

502.25

SRO065

22q13.2

Dup

69.15

SRO066
SRO067
SRO068
SRO069
SRO070
SRO071
SRO072
SRO073
SRO074
SRO075

22q13.33
22q13.33
22q13.33
22q13.33
Xp11.22
Xp11.22
Xp11.22
Xp11.22
Xp22.31
Xp22.31

Del/Dup
Del/Dup
Del/Dup
Del/Dup
Del/Dup
Dup
Del/Dup
Dup
Del/Dup
Del/Dup

8.67
3.06
2.01
8.77
2.7
0.21
7.86
1.58
150.48
16.6

BCR *
RBFOX2
C22orf46, CCDC134,
CENPM, CYP2D6,
CYP2D7P, CYP2D8P,
FAM109B, HMGN2P10,
LINC00634, MEI1,
MIR33A, MIR378I, NAGA,
NDUFA6, NDUFA6-AS1,
NHP2L1, OLA1P1,
RNU6-476P,
RNU6ATAC22P, SEPT3,
SHISA8, SLC25A5P1,
SMDT1, SREBF2 *, TCF20
*, TNFRSF13C, WBP2NL
RN7SKP80, RNU6-513P,
RRP7A, RRP7B, SERHL,
SERHL2
MAPK11, PLXNB2 *
NCAPH2
SHANK3 *
HUWE1 *
MIR651
-

Most Common
Comorbid Phenotype **

Small for gestational age

* Candidate gene. ** This column includes the most common comorbid phenotype other than neurodevelopmental
abnormality. For a complete list of commonly comorbid phenotypes, please see Supplementary Table S4.

2.1. Candidate Genes
These SROs involved a total of 242 genes; 20 genes had an HI score ≤10%, and 36 had
a pLI score ≥0.9 [22]. A total of 43 genes met either of the criteria. Of these 43 genes,
40 (93%) had never been identified as being associated with hypospadias and were thus
identified as candidate genes (Table 2). DECIPHER does not provide triplosensitivity data,
but we expanded our analysis to include this data. Of the candidate genes, they either had
no evidence or record of triplosensitivity. Although the Xp11.22 region (SRO070-073) is
documented to be triplosensitive, the candidate gene HUWE1 within SRO073 is not [27]. Of
the 40 candidate genes, 30 (75%) had low tissue specificity; the only gene with specificity
for male tissues was EHF, which is tissue enhanced in ductus deferens, seminal vesicle, and
salivary gland [28]. Thirteen of the 40 candidates (33%) had a “high” protein expression score
in at least one of the male tissues for which protein expression scores are available (epididymis,
prostate, seminal vesicle, testis) [28] (Table S2).
Through literature review, we identified 80 genes previously published in association
with hypospadias as either being causative, a risk factor, or associated with isolated hypospadias in screening studies, as well as genes proposed as candidates in gene expression
studies or given their role in genital and gonadal development (Table S3). The majority of
these are sequence variations. Additionally, more than 600 genes were listed in OMIM® as
having at least one patient with hypospadias as a reported phenotype [29].
We also identified 14 recurrent copy number regions with sizes ranging from 0.21 kb
to 186.74 kb. These regions are gene deserts, or regions with no protein-coding genes.
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2.2. Common Comorbidities
Of the 469 DECIPHER cases with hypospadias, only two had no documented comorbidities (“isolated hypospadias”), and both only had one reported CNV. Of note, one of
these CNVs is the basis for SRO041, which is 30.67 kb narrower than the CNV; this SRO
contained 2 candidate genes, CYFIP1 and NIPA2. The remaining 467 DECIPHER cases
had anywhere from 2 to several dozen comorbid phenotypes affecting nearly all organ
systems [22]. The most commonly reported comorbidity present in at least three cases with
CNVs overlapping an SRO was neurodevelopmental abnormality, including intellectual
disability and neurodevelopmental delays such as global developmental delay or delayed
speech and language development (found in 24 SROs). Other abnormalities of the genitourinary system were found, including micropenis (3 SROs), cryptorchidism (1), and
hydronephrosis (1). Comorbidities found in multiple (2 to 4) SROs include short stature,
small size for gestational age, inguinal hernia, feeding difficulties in infancy, microcephaly,
hypertelorism, low-set ears, hearing impairment, abnormality of the pinna, anteverted
nares, micrognathia, and cleft palate. For other comorbidities and their proportions, please
reference Table S4.
3. Discussion
Human genital development is complex, controlled by an intricate network of factors
regulating endocrine function, organ development, and sex determination and differentiation. The fragility of this network is demonstrated by the high incidence of DSD worldwide,
estimated at 1:4500 to 1:5000 live births [30]. Patients with isolated hypospadias, even when
severe, are typically not referred for genetic testing. When initial hormonal analyses are
unremarkable, the abnormality is usually deemed an isolated anatomical atypia [31,32].
Therefore, the causes underlying most cases have not been found. Indeed, there were
only two patients with isolated hypospadias in the entire DECIPHER database. In this
study, chromosome microarray-based technology (CMA) identified many copy number
variations recurrently found in individuals with hypospadias, and sometimes with other
phenotypes as well. Although some genes have been implicated, the genomic etiology
of hypospadias remains poorly understood. Many genomic variants of individuals with
hypospadias are exceedingly rare, making genotype-phenotype correlations uncertain
and thus clinical interpretation challenging. While a small number of CNVs have been
identified in individuals with hypospadias, they have either focused on large (>1.5 Mb)
CNVs or studied few (<30) participants [21,26]. In fact, few CMA studies have investigated
small (<1 Mb) CNVs in any human genetic disorder [33]. Thus, the contribution of CNVs,
especially those with few genes, to the etiology of hypospadias remains largely unexplored.
The use of large, multi-institutional databases allows for the identification of individuals that share both phenotypic features and gene variants, which can improve certainty in
gene pathogenicity and may allow for clarification of the role of novel genes in development, physiology, and disease. The largest of such databases to date is DECIPHER, which
compiles genotype and phenotype information of more than 35,000 individuals from over
250 centers around the world [22].
Use of these large-scale databases can allow for the identification of small CNVs recurrent among database participants with certain phenotypes. Historically, CNVs reported in
association with syndromes have been large, containing many genes. However, the advent of
publicly available, high-resolution CNV maps (with CNVs as small as 50 bp) now allows for
comparison of overlapping CNVs of various sizes to identify SROs, or the smallest common
CNV associated with a specific phenotype [34,35]. More recently, SROs as small as 5.2 kb
have been identified upstream of SOX9 in patients with DSD [20]. These data, then, provide
an opportunity to construct maps of these SROs across the genome. Rather than the large,
nonspecific CNVs previously reported with various genetic syndromes, these small CNVs
sometimes contain one or few genes, intragenic regions, and regulatory regions. Importantly,
these maps may assist with shrinking the genomic “gap” in understanding human genetic
disorders, especially phenotypes with complex etiologies such as hypospadias.
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Our findings illuminate for the first time many potential candidate genes not previously thought to play a role in hypospadias etiology, as well as many chromosomal
structural imbalances that may serve as risk factors for this and other phenotypes. Additionally, these results demonstrate the powerful potential of chromosome microarray-based
analysis in the discovery of genetic factors contributing to diseases with complex etiologies.
3.1. Hypospadias and Sex Chromosomes
It might be assumed that all cases of hypospadias are exhibited by Y chromosomebearing patients (e.g., XY, XXY). However, DECIPHER had several cases reported as 46XX
and even more reported as “other” or “unknown.” Given that hypospadias may occur in
the spectrum of DSD, it is imperative that sex chromosomes are reported and analyzed
when performing research on this and other conditions related to DSD [36]. Since the major
classification of DSD is based on sex chromosomes, it may be helpful to include the reason
why sex chromosomes are listed as “other” or “unknown.”
The Y chromosome has long been speculated to be associated with hypospadias; some of
the earliest research on the genetics underlying the condition described several cases with a
variety of translocations and deletions on this chromosome [37]. However, the lack of SROs
found on the Y chromosome support more recent research that has found no CNVs on this
chromosome, including SRY, in patients with isolated hypospadias [38,39]. The lack of SROs
on this chromosome and chromosome 2 are also in agreement with a paper that found no
recurrent and overlapping CNVs in patients with DSD on either of these chromosomes [33].
3.2. SRO Relationships to Previously Described Regions and Genes
Our study found very few SROs that overlapped with previously described regions
or genes. This is in agreement with the fact that existing studies have largely associated
cases of hypospadias with sequence variations, rather than CNVs [2] (Table S3). However,
this may change given the recent increase in CMA utilization, use of gene-targeted CMA,
increased data sharing through DECIPHER, or increased genetic evaluation of patients
with hypospadias.
3.3. Candidate Genes
One study used DECIPHER to identify recurrent CNVs in patients with isolated (“nonsyndromic”) congenital genitourinary anomalies [40]. That study identified RBFOX2 as a
candidate gene and used mouse models to explore its role in upper and lower genitourinary
tract development. Our study used a similar approach to identify SROs; however, it explored
the whole genome and utilized the CNVs of patients with both syndromic and non-syndromic
hypospadias. Through these methods, we identified many regions and genes that have never
been reported as being associated or potentially associated with hypospadias.
Certain candidates have high tissue specificity, both within and outside of the male
urogenital system [12] (Table S2). Some SROs containing these candidates had common
comorbidities related to the extra-urogenital tissues in which they are enhanced. For
example, DLGAP1 (SRO052) and GRIN2A (SRO048) are tissue enriched in the brain, and the
majority of cases within these SROs had neurodevelopmental abnormalities. Additionally,
PTPRD is tissue enhanced in the brain, and 7 of 11 cases in the SRO (SRO030) were also
reported to have intellectual disability, and 4 cases had microcephaly.
Many candidate genes with tissue specificity did not have recurrent phenotypes in this
study population, such as RBM8A (SRO002), which is tissue enriched in blood. However,
more in-depth investigation of these tissues in individuals with relevant CNVs may identify
common comorbidities. Additionally, investigation of cases with hypospadias and variants
in genes enriched in multiple tissues (e.g., ADAMTSL1, BDNF) may potentially lead to the
identification of new syndromes, or the expansion of phenotypes for existing syndromes.
Of the 40 candidate genes, it would seem prudent to most strongly consider those
candidate genes with high specificity and expression in “male tissues” (e.g., EHF, EP400,
RBM8A, SNED1, YWHAE, ZC3H18). However, that should not discount those genes
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expressed at low levels in male tissues, which may demonstrate important temporal expression. Such candidate genes for which the SRO is composed mostly of duplications (e.g.,
DBN1) may suggest that overexpression disrupts typical urogenital development, and those
with mostly deletions (e.g., ADAMTSL1, BDNF, COL4A1) may suggest haploinsufficiency.
For candidate genes, further investigation of tissues in which they are highly expressed—
and potentially associated phenotypes—may allow for the identification of common comorbidities (or, potentially, novel syndromes) associated with certain CNVs. For example, DLGAP1
and GRIN2A are enriched in brain tissue, and 12 of the 13 cases with relevant CNVs feature
neurodevelopmental abnormalities. Although cases with CNVs overlapping PTPRD (enhanced
in parathyroid tissue) were not explicitly reported to have parathyroid-related abnormalities,
further investigation may uncover relevant comorbidities. The same could be said for cases
with CNVs affecting RBM8A (enriched in blood) and hematologic disorders. Additionally,
data regarding co-expression, physical interactions, predicted co-expression, genetic interactions, co-localization, and shared protein domains may provide important clues for further
functional study [41].
3.4. Syndromes
SROs were found within loci known to be relevant to syndromes that have previously
been associated with hypospadias. Identification of SROs within these loci—and especially
candidate genes—may provide insight into the specific genetic etiology of hypospadias for
that syndrome. For example, Hunter–McAlpine Syndrome is associated with hypospadias,
as well as other phenotypes such as intellectual disability, microcephaly, and short stature.
The syndrome is known to be caused by a partial duplication of 5q35-qter [42], although
the specific region of this duplication underlying hypospadias has never been proposed.
SRO018 is within this locus and is composed of only cases with duplications; this SRO
contains candidate genes DBN1 and NSD1, which may contribute to hypospadias etiology
in these cases. SROs with candidate genes were found in the established risk loci for other
syndromes known to be associated with hypospadias, such as Silver–Russell Syndrome
(PSMD13); 13q Deletion Syndrome (COL4A1); and 22q Deletion/Duplication Syndromes,
which includes DiGeorge Syndrome (CRKL).
In addition, several SROs were located within known susceptibility regions for genetic
syndromes for which hypospadias is not a commonly associated phenotype. These findings
suggest that hypospadias may be investigated further as a potential syndromic feature, and
that individuals with relevant CNVs and hypospadias may need to be evaluated further
for comorbidities associated with these syndromes.
For example, SRO041 overlaps with the newly established Burnside–Butler Syndrome,
which is associated with various developmental and psychiatric disorders [43]. Notably,
three of four cases included in this SRO have delayed speech and language development.
This SRO contains two candidate genes, CYFIP1 and NIPA2, both of which are highly
expressed in ductus deferens, testis, epididymis, seminal vesicles, and prostate [28]. Both
genes have been implicated in Burnside–Butler Syndrome, although hypospadias has not
yet been identified as a comorbidity. Additional examples of such syndromes and SROs
can be found in Table S5.
3.5. Common Comorbidities
For almost 50 years, hypospadias has been associated with an increased risk of other
congenital comorbidities, especially cryptorchidism [37]. One study suggests that as high as
29.4% of cases have additional comorbidities—often urogenital, but also extra-urogenital [3].
Genitourinary comorbidities were indeed common in our population, found as a recurrent
phenotype in 5 SROs, although other common comorbidities affected a variety of organ
systems. Another study found that individuals with hypospadias are more likely to be
diagnosed with intellectual disability, autism spectrum disorder, and other behavioral or
emotional disorders [44]. Although they did not provide a conclusive explanation for these
findings, the increased risk persisted after adjusting for known genetic syndromes, suggesting
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a complex model of heritability that may be confounded by environmental, psychosocial, and
endocrine factors. However, this potentially suggests that there may be unknown genetic
syndromes involving both hypospadias and neurodevelopmental abnormalities. Our study
found similar results, as 24 of the 75 SROs (32%) had neurodevelopmental abnormality as a
phenotype present in at least three cases contributing to the SRO.
One paper found that 28% of the patients they studied—those with both hypospadias and neurodevelopmental delay—also had cardiovascular abnormalities [45]. They
identified various syndromes associated with similar constellations of comorbidities, citing
several pathogenically implicated genes as modulators of transcription and epigenetic
regulation that may serve related functions in development. Indeed, our methods identified three SROs featuring neurodevelopmental delay and cardiovascular abnormalities as
shared comorbidities. SRO008 contains SMYD3, a transcriptional regulator, and SRO030
contains candidate gene PTPRD, which plays an important role in memory, learning,
and synaptic plasticity [29]. SRO023 contains DPP6, which is associated with hereditary
ventricular fibrillation, as well as autosomal dominant (AD) microcephaly and neurodevelopmental delay which was replicated on knockdown of DPP6 in mice [29]. A CNV analysis
of patients with AD microcephaly identified two small de novo deletions in the gene [46];
which is supported by SRO023, which is composed of 13 deletions and only 3 duplications.
Such findings suggest a potential regulatory role for DPP6 in cardiac, neurological, and
genital development.
3.6. Recommendations
Our findings provide further support for genomic influences in the etiology of hypospadias. Hypospadias is thought to arise during external genitalia development, between
gestational weeks 8–12, due to incomplete fusion of the labioscrotal folds [38]. The roles
of these genes in the development of hypospadias will be elucidated by studying spatial
and temporal expression during this development of the urethra and nearby structures.
These findings, in concert with existing genetic and environmental studies, the DECIPHER
database, and animal models [47], will facilitate the functional studies needed to understand the roles of these genes in the genetic etiology of hypospadias, as well as in the
broader context of urogenital development.
In addition, these findings call for more frequent genomic analysis in patients found to
have hypospadias, which may further elucidate candidate genes for this condition as well as
novel genes involved in human genital development. Ideally, this analysis should include
both sequencing and genome-wide CNV analyses. Additionally, the specific category of
hypospadias (e.g., coronal, penoscrotal) should be reported in public databases to improve
genotype-phenotype correlation. Although increased hypospadias severity has been found
to be associated with increased likelihood of identifying likely pathogenic variants, patients
with even mild hypospadias can benefit from genetic testing, which may provide early
diagnoses, reveal undiagnosed syndromes, or identify candidate genes or variants [48].
Indeed, these results echo recommendations from panels of international experts for the
appropriate diagnostic approach to DSD. These recommendations highlight the importance
of increased genetic testing and results sharing in centralized databases such as DECIPHER
to promote functional studies that allow for the identification of novel implicated genes
and variants [49].
As our understanding of comorbidities associated with different structural abnormalities unfolds, CMA may allow for earlier screening and detection. For example, it
has been suggested that WT1 testing is not indicated in isolated hypospadias without
cryptorchidism, but there have been several reports of patients with such phenotype who
later develop Wilms tumors [31]. Recent research suggests that although genetic evaluation
of patients with proximal (severe) hypospadias is not the typical standard of care, when
evaluated, many are found to harbor clinically relevant genetic variations, supporting increased genetic evaluation of these individuals [26,32]. In addition, as the understanding of
the genetic etiology of this phenotype improves, genetic counseling for families may better
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inform estimates of recurrence risk for subsequent pregnancies. Improved understanding
of comorbidities may also allow for the provision of anticipatory guidance to parents, and
thus earlier detection and treatment.
4. Materials and Methods
4.1. CNV Data Sources
DECIPHER was queried to identify all cases with “hypospadias” as a listed phenotype [22], which included those with the HPO term HP:0000047 “hypospadias” as well as
HPO terms further defining hypospadias as penile, penoscrotal, glandular, perineal, midshaft, scrotal, or coronal. All cases were included, regardless of karyotype. CMA data were
also obtained from 32 patients with hypospadias referred to our center since 2008. CMA
data for patients from our center were acquired following the methods previously described
in “Integrated Small Copy Number Variations and Epigenome Maps of Disorders of Sex
Development” [33]. CMA data from these 32 cases had not yet been submitted to DECIPHER.
To construct the whole-genome CNV map described in this study, we used the karyotype map function of DECIPHER to identify chromosome regions with three or more
recurrent and overlapping deletions or duplications. From such regions, the smallest region
of overlap (SRO) is defined (Figures S1 and S2). We then integrated the CNV data obtained
from our center. Only SROs less than 1 Mb in size were included in this analysis.
Other genomic information collected for each SRO includes size, base-pair coordinates,
chromosome locus, and gene content. We analyzed all genes within the SROs using
DECIPHER’s predictive tools such as haploinsufficiency index (HI) (scores of ≤10% indicate
a high likelihood of exhibiting haploinsufficiency) [50] and pLI (score of ≥0.9 indicates
very low tolerance to loss of function mutations) [28]. In accordance with prior studies
using these cutoff values [28,50], genes that met either of these criteria and had never been
previously described in association with hypospadias were deemed candidate genes. In
addition to genotype information, the spectrum of phenotypes in patients with CNVs
included in the SRO was also analyzed. These SROs were cross-referenced with loci listed
for the nine hypospadias phenotype entries in OMIM® as well as previously described
CNVs associated with hypospadias [11].
4.2. Limitations
Our analysis of potential common phenotypes was limited by how cases were entered
in DECIPHER and our genetic database, including which phenotypes were reported. For
example, depending on when participants’ phenotypes were last updated, or their age of
death, age-related phenotypes (e.g., malignancy, short stature, intellectual disability, behavioral/emotional disorders) may not have yet manifested. In addition, distal hypospadias
may not even be clinically recognized, much less reported in DECIPHER, so there is likely
under-reporting of the phenotype in this database.
When using public databases, different array technologies used by reporting institutions
may lead to differences in the reported size of CNVs that are actually identical [51]. For that
reason, the coordinates of our SROs should not be considered absolute or definitive loci.
Although HPA lists tissue specificity and expression levels in several “male tissues,”
they do not list values for tissues specifically associated with urethral or penile development;
therefore, these values should only be regarded as an estimate.
SROs that contain no genes may hold important regulatory regions. We identified
three such SROs within what OMIM® describes as a susceptibility locus for X-linked
hypospadias [11], which were all located less than 3.5 Mb downstream of DGKK, the
gene most commonly associated with hypospadias [2,52,53]. These regions may contain
key regulatory elements for DGKK not previously understood in relation to hypospadias
pathogenesis, such as those recently found for SOX9 while using a similar method to
identify SROs [54]. However, analyzing these regions is beyond the scope of this paper and
should be considered an area for future study.
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Finally, many candidate genes have been proposed to be associated with this phenotype, but such studies often report small numbers of cases and controls. Often, they
are not able to be replicated in future studies, although this could be due to differences
in study populations. Additionally, this study does not address the non-genetic factors
contributing to hypospadias such as environmental, psychosocial, and endocrine factors.
These studies, as well as our results, should not be interpreted as asserting causation, but
rather as preliminary data for future areas of functional research to further understand the
genetic etiology of hypospadias.
5. Conclusions
This study used chromosome microarray-based technology (CMA) to identify genomic
structural variations recurrently found in individuals with hypospadias, a common congenital atypical sex development. These findings propose many of these loci and the candidate
genes within them as novel potential underlying causes of hypospadias and, occasionally,
additional comorbid phenotypes. However, given that the role of non-genetic factors remains to be explored, these candidate genes should be investigated with functional studies
that will further determine their potential relevance to hypospadias. Recurrent losses and
gains of DNA were detected on nearly all chromosomes, suggesting genome-wide CMA
as an ideal assessment tool for this population. Increased genetic screening of individuals
with hypospadias, as well as reporting these data to collaborative databases, will improve
detection of common comorbidities as well as additional candidate genes. These results
provide insight into many novel risk loci and genes for further investigation to improve
understanding of the genetic etiology of this common, yet poorly understood condition, as
well as human genital development overall.
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